The record
Every action on file
36 regulatory or legal actions against 18 of the 33 providers on this site. Each links to the primary document — an FDA letter, a court filing, a regulator’s own announcement. Nothing here is sourced from a blog.
By date
2026-07
Hims — FTC, State of Utah and Los Angeles County sued Hims & Hers under FTC Act section 5 and ROSCA over alleged health-data disclosure to Meta and Snap, charging before the promised provider consult, and cancellation deadlines set about two days before an early refill date; allegations unproven.
2026-07
Willow — Reopened NAD matter closed after Willow Health Services voluntarily discontinued claims that its compounded semaglutide was proven to support weight loss, delivered results comparable to FDA-approved semaglutide, and produced effective weight loss without diet or exercise.
2026-07
Hers — FTC, State of Utah and Los Angeles County sued Hims & Hers, the same legal entity, over alleged health-data sharing and subscription billing practices; allegations unproven.
2026-06
Eden — FDA warning letter to Eden Health International, Inc. dba Eden (MARCS-CMS 728279).
2026-06
OrderlyMeds — FDA warning letter to OrderlyMeds LLC dba OrderlyMeds (MARCS-CMS 728291), part of the June 2026 round over compounded GLP-1 marketing.
2026-05
Noom (Noom Med) — NAD (BBB National Programs) decision, challenged by Eli Lilly, recommended Noom discontinue or modify its 'Microdose GLP-1Rx' claims for lack of support that the lower dose delivers a measurable health benefit; Noom disagreed but agreed to comply.
2026-04
Zealthy — DOJ/FTC filed an amended complaint seeking an immediate asset freeze and receivership against Zealthy and CEO Kyle Robertson, alleging foreign call-centre contractors and unlicensed non-clinicians ordering prescriptions, doctors' names and NPIs used without their knowledge, unauthorised card charges while cancellation attempts were blocked, and misuse of patients' health information for social media marketing; Zealthy also lost its LegitScript certification in 2025.
2026-03
Hims — Novo Nordisk patent infringement suit filed February 2026 was dropped 9 March 2026 under a settlement in which Hims agreed to stop promoting compounded GLP-1s.
2026-03
Hers — Novo Nordisk patent suit dropped March 2026 under a settlement requiring Hims & Hers to move patients to FDA-approved products.
2026-02
Willow — Eli Lilly sued Willow Health Services, Inc. (C.D. Cal., 2:25-cv-03570) in April 2025 over compounded tirzepatide; the case was dismissed with prejudice on 3 February 2026 at the pleading stage for failure to plead proximate causation, without any ruling on whether the marketing was misleading.
2026-02
Mochi Health — Washington State Department of Health investigation into Mochi-affiliated pharmacy Aequita following whistleblower allegations of unlicensed workers packaging compounded GLP-1s, vials sourced from Alibaba and contaminated vials; WA DOH identified multiple violations and temporarily restricted the compounding license.
2026-02
Ivím Health — FDA warning letter to Ivim Services LLC dba Ivim (MARCS-CMS 721816), part of the February 2026 telehealth action over compounded GLP-1 marketing.
2026-02
MEDVi — FDA warning letter to MEDVi, LLC dba MEDVi (MARCS-CMS 721455) alleging the products carried MEDVi branding that falsely suggested MEDVi was the compounder, that claims such as 'same active ingredient as Wegovy and Ozempic' implied FDA approval, and that the products were misbranded under FD&C Act sections 502(a) and 502(bb), with seizure, injunction and border detention warned as possible consequences.
2026-02
Strut Health — FDA warning letter to Strut Health, LLC dba Strut (MARCS-CMS 721448).
2025-12
Willow — NAD (BBB National Programs) decision challenged by Novo Nordisk recommended discontinuing or modifying health claims for compounded semaglutide tablets; Willow Health Services did not provide a compliance statement and NAD referred the matter to the FTC, state Attorneys General and advertising platforms.
2025-09
Hims — FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing.
2025-09
Hers — FDA warning letter to Hims & Hers Health, Inc. dba Hers (MARCS-CMS 716825) over compounded GLP-1 marketing.
2025-09
LillyDirect — FDA warning letter to Eli Lilly and Company over a prime-time TV special that created a misleading impression regarding product safety.
2025-09
NovoCare Pharmacy — FDA warning letter to Novo Nordisk, Inc. over a prime-time TV special that created a misleading impression regarding product safety.
2025-06
Hims — Novo Nordisk terminated its collaboration with Hims & Hers, alleging illegal sham compounding and Chinese-sourced unapproved API.
2025-04
Mochi Health — Eli Lilly sued Mochi Health (N.D. Cal.) alleging sale of unauthorized tirzepatide copies including oral versions and formulations mixed with additives such as glycine.
2025-04
Henry Meds — Eli Lilly sued Henry Meds (N.D. Cal.) over unauthorized tirzepatide copies, in the same four-defendant action that named Mochi Health, Fella Health/Delilah and Willow Health Services.
2024-04
Zealthy — Zealthy CEO Kyle Robertson is the founding CEO of Cerebral, which settled FTC/DOJ charges over data sharing and deceptive cancellation practices.
Undated
On record, but without a date we could confirm from the source document.
Hims — Pending securities class action over Novo-related disclosures.
Willow — BBB profile for 'Start Willow' (Austin TX) rating D, not accredited, with 5 complaints of which 1 unanswered.
Willow — Third-party review reports Willow uses three compounding pharmacies (Red Rock Home Pharmacy, Epiq Pharmacy, The Pharmacy Hub) and that cancellation language conflicts between the FAQ and the informed-consent document.
Mochi Health — Novo Nordisk has also filed suit against Mochi Health.
Mochi Health — BBB rating A but not accredited, with 1,378 complaints; themes include membership and medication subscriptions having to be cancelled separately, charges continuing after cancellation, and medication arriving heat-damaged.
Zealthy — BBB not accredited with a Pattern of Complaints alert, 2,484 complaints over three years and 852 closed in the last 12 months; BBB publishes only one in five complaints due to volume.
Eden — BBB rating F, not accredited, with a Pattern of Complaints alert and 109 complaints of which 84 received no response; themes are unauthorized and duplicate charges, unanswered messages and medication changed without notification.
Henry Meds — BBB rating F, not accredited, with 232 complaints of which 26 unanswered; BBB states concerns primarily involve billing, cancellation and fulfillment issues.
Noom (Noom Med) — $62M class action settlement (Mahood v. Noom) over auto-enrollment and auto-renewal practices, final approval granted.
Amble Health — BBB rating F, not accredited, with a Pattern of Complaints alert, 185 unanswered complaints and 11 unresolved; themes are refunds, payment problems and non-delivery.
LifeMD — BBB rating A but 827 complaints in the reporting period, with recurring themes of difficulty cancelling subscriptions and refund problems; BBB publishes only one in five complaints due to volume.
Ro (Ro Body) — BBB rating B with 645 complaints in the three-year window, with recurring themes of surprise charges above the quoted price and unauthorized billing.
TrimRx — BBB rating F, not accredited, with a Pattern of Complaints alert, 728 complaints receiving no response and 221 unresolved; BBB states consumers allege charges before medical approval, charges different from the amount selected, ignored cancellation requests and undisclosed fees.
By provider
Why so much of this happened at once
Between September 2025 and March 2026 the FDA issued roughly 85 warning letters to telehealth companies selling compounded GLP-1s. The objection was rarely the compounding itself, which is legal. It was the marketing: describing a compounded drug as a generic version of, or the same as, an approved one; implying FDA approval; or advertising the drug under the telehealth company’s own brand without saying where it came from.
In February 2026 the agency went further and moved to restrict the active ingredients used in non-approved compounded GLP-1 products. That is why several companies on this site now supply FDA-approved medication when a year ago they did not — and why a price you saw quoted in 2025 may not exist any more.